Ignite Creation Date:
2025-12-24 @ 5:05 PM
Ignite Modification Date:
2026-01-25 @ 3:28 AM
Study NCT ID:
NCT05745350
Status:
RECRUITING
Last Update Posted:
2025-02-11
First Post:
2023-02-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Sponsor:
Xiaorong Dong
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Small Cell Lung Cancer Extensive Stage | View |
Keywords: